Neurogene Inc. (NASDAQ: NGNE) is a Healthcare company (Biotechnology) with a market capitalization of $365M. The Maz Rating grades it against the other companies in its sector.
Neurogene Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $23.10, Neurogene Inc. trades at 1.8x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -44.4%, return on invested capital of -35.8% and a free cash flow yield of -26.5%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 19.97. Over the past 52 weeks the share price ranged from $15.93 to $43.66, with a beta of 2.09.
Neurogene Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 6 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Neurogene Inc. (NGNE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 51.6% / 30% · Interest income / Revenue 323800000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 51.6% / 33% · Receivables / Mkt Cap (36m) 0.03% / 49% · Interest income / Revenue 323800000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 51.6% / 33.33% · Receivables / Mkt Cap (24m) 0.03% / 33.33% · Interest income / Revenue 323800000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.78% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 93.5% / 33.33% · Receivables / Avg Assets (4Q) 0.06% / 33.33% · Interest income / Revenue 323800000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 95.2% / 33.33% · (Cash+Recv) / Total Assets 95.3% / 33.33% · Interest income / Revenue 323800000.0% / 5% | Fail |
No. As of September 2026, Neurogene Inc. (NGNE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Neurogene Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 323800000.0% of each dividend: Neurogene Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.